Advertisement
BAX vs BDX
Which Stock Would AI Choose? Baxter International (BAX) vs. Becton, Dickinson and Company (BDX) Stock Comparison
1) Key Takeaways
- BAX is a turnaround story: after divesting its Kidney Care business, Baxter raised its 2026 sales outlook on strong quarterly growth, but margins remain under pressure.
- BDX is a more focused medical technology company following its life sciences spin-off, with higher operating margins and broader diversification across four segments.
- BDX generates materially stronger profitability (adjusted operating margin near 25%) versus BAX (near 14%), reflecting different business-quality profiles.
- BAX shares have surged in recent months on turnaround optimism, yet execution risks such as the Novum IQ infusion-pump hold persist.
- BDX offers steadier, higher-quality growth with exposure to fast-growing drug-delivery and monitoring platforms, while BAX skews toward a value-recovery trade.
2) Introduction
Baxter International and Becton, Dickinson and Company are two large-cap medical technology names that often attract the same pool of healthcare investors, yet they sit at very different points in their corporate lifecycles. Both have recently completed major portfolio reshaping — Baxter through the sale of its Kidney Care unit and BD through the spin-off of its life sciences business — making a direct comparison especially timely. This stock comparison is relevant to investors weighing a higher-risk turnaround in BAX against a more established, quality-oriented compounder in BDX, and to traders evaluating relative performance and market positioning across the healthcare sector.
3) BAX Overview and Recent Performance
BAX (Baxter International Inc.) supplies a broad portfolio of hospital and clinical products, including infusion therapies, advanced surgery, injectables and drug compounding. The company's recent narrative centers on a post-divestiture turnaround after selling its Kidney Care business (now Vantive) in early 2025, leaving a leaner, more focused medical-products platform.
Recent quarters have shown improving top-line momentum. In its latest report, Baxter posted revenue of roughly $2.96 billion, up about 5% on an organic basis, with standout growth in Advanced Surgery (up roughly 12%) and drug compounding. Management raised its 2026 sales growth outlook to 3%–4% and lifted adjusted earnings guidance to $1.95–$2.15 per share. Sentiment has responded strongly, with shares rallying sharply over recent months on the improved guidance.
That optimism is tempered by profitability. Adjusted gross margin compressed to about 38.6% and adjusted operating margin to roughly 14.2% amid tariffs, higher manufacturing costs and inventory carryover. The ongoing shipment-and-installation hold on the Novum IQ large-volume infusion pump remains a key overhang, and the company reduced its quarterly dividend, underscoring an emphasis on balance-sheet repair.
4) BDX Overview and Recent Performance
BDX (Becton, Dickinson and Company, commonly "BD") is a diversified medical technology leader operating across four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The company completed the spin-off of its Biosciences and Diagnostics (life sciences) business, which was combined with Waters Corporation in February 2026, sharpening its focus as a pure-play medtech.
In its most recent fiscal quarter, BD reported revenue of approximately $5 billion, up 4.4% on a currency-neutral basis, with adjusted earnings per share (EPS) of $3.23, up 4.9% year over year. Management raised the midpoint of its full-year adjusted EPS outlook to a range of $12.62–$12.72. Adjusted operating margin stood near 24.9%, reflecting stronger profitability than Baxter's. Growth was led by double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, supported by roughly 100 signed agreements across GLP-1 programs (a class of injectable therapies for diabetes and obesity).
Offsetting factors include an FDA (U.S. Food and Drug Administration) warning letter tied to its El Paso, Texas facility, which prompted a temporary ship hold on certain infection-prevention products, and a net leverage ratio near 2.9 times. Still, BD's broader diversification and higher margins generally support steadier sentiment.
5) Trending AI Robots
Tickeron's Trending AI Robots page curates the platform's most suitable automated strategies for current market conditions from a universe of hundreds of AI trading bots that collectively trade thousands of different tickers. Each bot carries its own trading style, strategy, timeframe, performance history and set of tickers, with metrics such as win rate, profit factor and realized return published openly. The curated section typically highlights a smaller selection of top performers — for example, roughly 21 featured bots chosen from hundreds available — spanning sectors from semiconductors to healthcare, with reported results that can range from double-digit to over 90% depending on the strategy and period. Because no two bots are alike, the page is designed to help traders quickly identify those best aligned with today's market. Explore the full lineup of Trending AI Robots to evaluate which strategies match your approach.
6) Head-to-Head Comparison
Despite operating in the same sector, BAX and BDX represent contrasting investment profiles. BD is larger and more diversified, with recurring consumables revenue and materially higher operating margins, giving it a quality-compounder profile. Baxter is a more concentrated turnaround play, where the investment case hinges on margin recovery, cost discipline and resolution of the Novum IQ hold.
Growth drivers also differ. BDX is leveraged to secular trends in biologic drug delivery (including GLP-1 programs), advanced patient monitoring and vascular intervention. BAX is anchored in hospital consumables, IV (intravenous) solutions, surgery and drug compounding — dependable but lower-growth categories. On momentum, BAX has delivered stronger recent share-price gains as expectations reset higher, while BDX has shown steadier, less volatile appreciation.
Risk profiles diverge as well. Baxter faces margin compression, tariff pressure and product-quality overhangs alongside a reduced dividend. BD faces its own regulatory and facility headwinds, elevated leverage and tariff exposure, but its diversified base and stronger free cash flow offer more cushion. In short, BAX offers higher potential upside with higher execution risk, while BDX offers consistency at a higher quality bar.
7) Tickeron AI Verdict
On observable factors, Tickeron's AI would likely lean toward BDX as the more consistent, trend-stable candidate. BD's diversified revenue base, stronger operating margins, rising EPS guidance and steadier price behavior present a cleaner, more durable trend profile. BAX carries more volatile momentum tied to turnaround catalysts and remains more exposed to margin and execution uncertainty. While a trend-following model may still flag BAX for its recent upside thrust, the combination of stability, margin quality and relative positioning would more likely favor BDX under current conditions.
8) Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Buy and BDX is a Hold.
Aroon Indicator for BAX shows an upward move is likely
BAX's Aroon Indicator triggered a bullish signal on October 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In 143 of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 24 of 45 cases over the following month. The odds of a continued upward trend are 53%.
BAX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 165 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 22 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for BAX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BAX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.082) is normal, around the industry mean (4.887). P/E Ratio (-12.072) is within average values for comparable stocks, (35.995). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.456). Dividend Yield (0.002) settles around the average of (0.006) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BDX's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for BDX moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 19 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 57 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BDX just turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 27 of 48 cases over the following month. The odds of a continued upward trend are 56%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 133 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 111 of 219 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.128) is normal, around the industry mean (4.887). P/E Ratio (57.452) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.456). BDX has a moderately high Dividend Yield (0.022) as compared to the industry average of (0.006). P/S Ratio (2.290) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
BAX | BDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 88 | |
SMR RATING 1..100 | 94 | 85 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 59 | 7 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (71) in the Medical Specialties industry is in the same range as BAX (95). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as BAX (100). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's SMR Rating (85) in the Medical Specialties industry is in the same range as BAX (94). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's Price Growth Rating (50) in the Medical Specialties industry is in the same range as BAX (50). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's P/E Growth Rating (7) in the Medical Specialties industry is somewhat better than the same rating for BAX (59). This means that BDX’s stock grew somewhat faster than BAX’s over the last 12 months.
| BAX | BDX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 47% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 55% |
| MACD ODDS (%) | 2 days ago 53% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 52% |
| Advances ODDS (%) | 8 days ago 57% | 6 days ago 45% |
| Declines ODDS (%) | 2 days ago 68% | 2 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 0 FA rating(s) are green while BDX’s FA Score has 1 green FA rating(s).
- BAX’s FA Score: 0 green, 5 red.
- BDX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while BDX’s TA Score has 6 bullish TA indicator(s).
- BAX’s TA Score: 5 bullish, 5 bearish.
- BDX’s TA Score: 6 bullish, 4 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а -1.53% price change this week, while BDX (@Pharmaceuticals: Other) price change was +3.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.77%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +7.55%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
BDX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with LUNG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | -1.92% | ||
| LUNG - BAX | 53% Loosely correlated | +4.00% | ||
| ICUI - BAX | 52% Loosely correlated | -0.10% | ||
| STE - BAX | 51% Loosely correlated | +1.45% | ||
| SYK - BAX | 51% Loosely correlated | +2.17% | ||
| BDX - BAX | 49% Loosely correlated | +1.60% | ||
More | ||||
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +1.60% | ||
| COO - BDX | 55% Loosely correlated | +1.65% | ||
| TMO - BDX | 50% Loosely correlated | +1.18% | ||
| BAX - BDX | 50% Loosely correlated | -1.92% | ||
| CNMD - BDX | 48% Loosely correlated | +3.32% | ||
| MMSI - BDX | 48% Loosely correlated | +1.36% | ||
More | ||||